ANL vs ZLAB vs LEGN vs ZYME vs JPM vs KO

For growth investors, Legend Biotech Corporation (LEGN) is the stronger pick with 64.

0% revenue growth year-over-year, versus -100. 0% for Adlai Nortye Ltd. (ANL). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Adlai Nortye Ltd. (ANL) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus The Coca-Cola Company at 27. 2x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -90. 0% for Zai Lab Limited (ZLAB). Over 10 years, the gap is even starker: JPM returned +465. 8% versus ZLAB's -38. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Adlai Nortye Ltd. 's 1. 39β — meaning ANL is approximately -795% more volatile than KO relative to the S&P 500. On balance sheet safety, Zymeworks Inc. (ZYME) carries a lower debt/equity ratio of 7% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Legend Biotech Corporation (LEGN) is pulling ahead at 64.

0% versus -100. 0% for Adlai Nortye Ltd. (ANL). On earnings-per-share growth, the picture is similar: Adlai Nortye Ltd. grew EPS 68. 3% year-over-year, compared to -64. 9% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -833. 1% for Adlai Nortye Ltd. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -996. 4% for ANL. At the gross margin level — before operating expenses — ANL leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 393. 3x for Legend Biotech Corporation — 378. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ANL: 151. 9% to $26. 00.

In this comparison, KO (2.

5% yield), JPM (1. 9% yield) pay a dividend. ANL, ZLAB, LEGN, ZYME do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, ANL: -31. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ANL (Healthcare) and ZLAB (Healthcare) and LEGN (Healthcare) and ZYME (Healthcare) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ANL is a small-cap quality compounder stock; ZLAB is a small-cap high-growth stock; LEGN is a small-cap high-growth stock; ZYME is a small-cap high-growth stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. JPM, KO pay a dividend while ANL, ZLAB, LEGN, ZYME do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.